Anticancer Research 2013-02-01

Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, including 3-bromopyruvate, 2-deoxyglucose and biguanides.

Michael A Lea, Mehreen S Qureshi, Michael Buxhoeveden, Nicolette Gengel, Jessica Kleinschmit, Charles Desbordes

Index: Anticancer Res. 33(2) , 401-7, (2013)

Full Text: HTML

Abstract

In previous studies performed by our group, we observed that 2-deoxyglucose blocked the acidification of the medium used for culture of colon cancer cells caused by incubation with biguanides and it had an additive inhibitory effect on growth. In the present work, we found that 3-bromopyruvate can also prevent the lowering of pH caused by biguanide treatment. 3-Bromopyruvate inhibited colonic cancer cell proliferation, but the effect was not always additive to that of biguanides and an additive effect was more notable in combined treatment with 3-bromopyruvate and 2-deoxyglucose. The induction of alkaline phosphatase activity by butyrate was not consistently affected by combination with other agents that modified glucose metabolism. The drug combinations that were examined inhibited proliferation of wild-type and p53-null cells and affected colonic cancer lines with different growth rates.


Related Compounds

  • 3-Bromopyruvic aci...
  • 2-Deoxy-D-glucose

Related Articles:

3-Bromopyruvate: A novel antifungal agent against the human pathogen Cryptococcus neoformans

2013-05-03

[Biochem. Biophys. Res. Commun. 434(2) , 322-7, (2013)]

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.

2014-07-15

[Oncotarget 5(13) , 5177-89, (2014)]

Insights into the carboxyltransferase reaction of pyruvate carboxylase from the structures of bound product and intermediate analogs.

2013-11-01

[Biochem. Biophys. Res. Commun. 441(2) , 377-82, (2013)]

Deprive to kill: glutamine closes the gate to anticancer monocarboxylic drugs.

2012-12-01

[Autophagy 8(12) , 1830-2, (2012)]

3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.

2012-02-01

[J. Bioenerg. Biomembr. 44(1) , 1-6, (2012)]

More Articles...